Linked Life Data

7846945

Source:http://linkedlifedata.com/resource/pubmed/id/7846945

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-3-9
pubmed:abstractText
Over the past five years, the results of six prospective randomized trials have set new standards in the primary and secondary prevention of thromboembolism in "nonvalvular" ("nonrheumatic") atrial fibrillation. On the one hand, they have confirmed the increased risk of stroke in these patients amounting to about 5% per year and an annual recurrence rate after a recent transient ischaemic attack or minor stroke of 12%. On the other hand, the results of these trials have unanimously demonstrated a > or = 60% risk reduction with oral anticoagulation at an acceptable risk of major bleeding complications. A reduced intensity of anticoagulant therapy with a target INR of 2.0-3.0 is effective in most of these patients. Both clinical and echocardiographic features allow the identification of subgroups at low or high risk of thromboembolic complications and provide the basis for the individual benefit-to-risk assessment of anticoagulant therapy. Aspirin is currently recommended as a second choice therapy for patients who are poor candidates for oral anticoagulants or who are considered to be at low risk for thromboembolism.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-5860
pubmed:author
pubmed:issnType
Print
pubmed:volume
83 Suppl 5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
49-58
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
[Prevention of embolisms in atrial fibrillation: anticoagulation and antiplatelet therapy].
pubmed:affiliation
Med. Klinik und Poliklinik, Univ. Münster.
pubmed:publicationType
Journal Article, English Abstract, Review